Professor Yige Bao: From “New Leaves Spur the Old” to “One Mountain Opens, Another Blocks the Way” —Reflections and Challenges in Post-Neoadjuvant Management of MIBC

Professor Yige Bao: From “New Leaves Spur the Old” to “One Mountain Opens, Another Blocks the Way” —Reflections and Challenges in Post-Neoadjuvant Management of MIBC

2026.02.04
Recently, the Beijing Academic Exchange Conference for Young Physicians in Urologic Oncology was successfully held in Beijing. The meeting focused on the latest frontiers in urologic oncology and brought together many leading mid-career and young experts from across China, aiming to elevate clinical practice through intellectual exchange.
ESMO Hot Topic Focus | Professor Richard S. Finn: Immunotherapy-Based Combinations Turn “Stone into Gold” — The TALENTOP Study Reshapes the Treatment Landscape of Advanced HCC

ESMO Hot Topic Focus | Professor Richard S. Finn: Immunotherapy-Based Combinations Turn “Stone into Gold” — The TALENTOP Study Reshapes the Treatment Landscape of Advanced HCC

2026.02.04
In the global field of hepatocellular carcinoma (HCC) treatment, the synergistic use of targeted therapy and immunotherapy has led to breakthrough progress, significantly prolonging survival for patients with advanced disease and bringing renewed hope to countless individuals. Yet medical progress never stands still. How to further transcend existing treatment paradigms and unlock deeper survival benefits remains a persistent goal for clinicians worldwide.
ESMO International Perspective | 42-Month Long-Term Follow-Up with Median OS of 22.8 Months: Professor Manon Allaire Interprets the Outstanding Real-World Performance of the “T+A” Regimen

ESMO International Perspective | 42-Month Long-Term Follow-Up with Median OS of 22.8 Months: Professor Manon Allaire Interprets the Outstanding Real-World Performance of the “T+A” Regimen

2026.02.04
The combination of atezolizumab plus bevacizumab (the “T+A” regimen) has established a new standard of care for first-line treatment of advanced hepatocellular carcinoma (HCC). However, the lack of long-term survival data and uncertainties regarding its effectiveness in complex real-world populations have remained major clinical concerns.
ESMO Expert Dialogue | From Chinese Innovation to Global Consensus — Landmark Interpretation of TALENTOP and New Horizons in Perioperative Therapy for Liver Cancer

ESMO Expert Dialogue | From Chinese Innovation to Global Consensus — Landmark Interpretation of TALENTOP and New Horizons in Perioperative Therapy for Liver Cancer

2026.02.04
Hepatocellular carcinoma (HCC) remains one of the deadliest malignancies worldwide. Approximately 60–70% of patients are diagnosed at intermediate or advanced stages, making the pursuit of innovative therapeutic strategies that deliver meaningful survival benefit a long-standing global challenge. Against this backdrop, the TALENTOP study, led by Fan Jia, Academician and Principal Investigator from Zhongshan Hospital, Fudan University, and presented orally at ESMO 2025 by Sun Huichuan, has drawn worldwide attention.
ESMO Global Perspective | Professor Arndt Vogel: From First-Line Advanced Disease to the Perioperative Setting—How Immunotherapy Combinations Are Redefining Hepatocellular Carcinoma Care

ESMO Global Perspective | Professor Arndt Vogel: From First-Line Advanced Disease to the Perioperative Setting—How Immunotherapy Combinations Are Redefining Hepatocellular Carcinoma Care

2026.02.03
With the rapid evolution of immunotherapy–targeted therapy combinations, the management of advanced hepatocellular carcinoma (HCC) has entered a new era. Yet for patients with traditionally high-risk features—such as macrovascular invasion or extrahepatic spread—clinical outcomes have historically remained poor, posing a persistent therapeutic challenge.
[The Lancet] Professor Yungang Tao: Breaking Two Decades of Stagnation—The NIVOPOST-OP Trial Redefines Postoperative Adjuvant Therapy for High-Risk Head and Neck Squamous Cell Carcinoma

[The Lancet] Professor Yungang Tao: Breaking Two Decades of Stagnation—The NIVOPOST-OP Trial Redefines Postoperative Adjuvant Therapy for High-Risk Head and Neck Squamous Cell Carcinoma

2026.02.03
For patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC) at high postoperative risk, the standard of adjuvant concurrent chemoradiotherapy (CRT) has remained unchanged since 2004—despite persistent rates of recurrence and metastasis. Recently, the NIVOPOST-OP trial, led by Yungang Tao of Gustave Roussy Cancer Center, was published in The Lancet, delivering the first definitive breakthrough in nearly 20 years.
Published in The BMJ: Professor Xu Zhang’s Team Conducts the World’s First RCT Demonstrating That the Reliability of Telesurgery Is Non-Inferior to Local Robotic Surgery

Published in The BMJ: Professor Xu Zhang’s Team Conducts the World’s First RCT Demonstrating That the Reliability of Telesurgery Is Non-Inferior to Local Robotic Surgery

2026.02.03
On January 28, a landmark study was published in the world-leading medical journal The BMJ. For the first time, a multicenter randomized controlled trial (RCT) has demonstrated that the reliability of urological telesurgery is non-inferior to conventional local robotic surgery.
From Evidence-Based Medicine to Strategic Sequencing: Rethinking and Breaking Through Whole-Course Immunotherapy in Urothelial Carcinoma

From Evidence-Based Medicine to Strategic Sequencing: Rethinking and Breaking Through Whole-Course Immunotherapy in Urothelial Carcinoma

2026.02.03
Recently, the Beijing Academic Exchange Conference for Young Physicians in Urologic Oncology was successfully held in Beijing. The conference brought together the emerging backbone of China’s urologic oncology community, aiming to promote standardized and innovative development in the diagnosis and treatment of urologic malignancies through cutting-edge academic discussion and clinical experience sharing.
CASH 2026 | Professor Hui Wei: Frontiers in Precision Therapy for AML and New Management Pathways for High-Risk Patients

CASH 2026 | Professor Hui Wei: Frontiers in Precision Therapy for AML and New Management Pathways for High-Risk Patients

2026.02.01
From January 9–11, 2026, the 6th China Hematology Discipline Development Conference (CASH) was held in Tianjin, bringing together leading experts to explore cutting-edge advances in hematology aligned with national health strategies. During the conference, Oncology Frontier – Hematology Frontier invited Professor Hui Wei from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, to provide in-depth insights into breakthroughs in FLT3 and IDH1/2 targeted therapy, precision strategies for elderly and high-risk AML populations, and MRD-guided dynamic treatment approaches, offering valuable perspectives for clinical practice and translational research.
CASH 2026 | Professor Lanping Xu: Advances and Optimization Strategies in Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia

CASH 2026 | Professor Lanping Xu: Advances and Optimization Strategies in Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia

2026.02.01
From January 9–11, 2026, the 6th China Hematology Discipline Development Conference (CASH) was held in Tianjin, bringing together leading experts to discuss cutting-edge advances in hematology and national health priorities. During the conference, Oncology Frontier – Hematology Frontier invited Professor Lanping Xu from Peking University People’s Hospital to share her team’s latest progress in hematopoietic stem cell transplantation (HSCT) for severe aplastic anemia (SAA), with a focus on long-term outcomes of haploidentical transplantation, as well as optimization of transplant timing, patient stratification, and donor selection.